London IN a survey of some of the problems involved in the clinical assessment of progestational agents (Swyer, 1960) it was suggested that since none of these agents possesses all the known properties of progesterone, and since the various properties are, in general, possessed in varying degrees, a number of different criteria should be employed for tests of comparative potency. The criteria considered were: (1) The production of subnuclear vacuolation in the endometrium following a five-day course of progestogen given to cestrogen-primed women with secondary amenorrhoea or amenorrhcea following castration. (2) The production of a midor late secretory endometrium in similar women following a ten-day course of progestogen, in both (1) and (2) two previous similar courses of cestrogen and progestogen having been given to sensitize the endometrium. (3) Withdrawal bleeding following a five-day course of progestogen in women with secondary amenorrhcea. (4) Postponement of menstruation in normal women given a twenty-day course of progestogen from the twentieth day of the cycle. (5) Depression of the karyopyknotic index in the vaginal smear. (6) Inhibition of the oestrogeninduced changes (including fern crystallization) in the cervical mucus of the patients mentioned in (1). (7) Inhibition of ovulation, which, it was suggested, might be determined by the ability of a course of progestogen given from the fifth to the twenty-fifth day of the cycle to produce a painless period in women complaining of "essential" dysmenorrhoea.
As a result of experience in trying to apply these criteria to tests of relative potency of progestogens in the human, it has become clear that there are formidable practical difficulties in the way of carrying out trials which would provide statistically reliable data. The most promising test is that involving postponement of menstruation (4, above), although the results obtained in this way do not necessarily agree with those obtained with tests (1) or (2). With these latter tests, however, statistical evaluation is not possible. This paper will consider our current data on postponement of menstruation, and will also refer to results obtained with withdrawal bleeding and to changes in the vaginal smear.
Postponement of menstruation. -Patients attending the Fertility Clinic at University College Hospital and in whom no significant abnormalities had been detected on routine investigation were instructed to take the progestogen tablets orally from the twentieth day of the cycle for twenty days or until the period began, whichever was the sooner. If menstruation was postponed until after the completion of the twenty-day course, treatment was resumed on the twentieth day of the next cycle at half the previous dose; if it began before the completion of the twenty-day course, treatment in the following cycle was at double the previous dose. In this way, it was hoped to establish for each substance tested the dose which would be effective in 50 % of patients and to provide the basis for probit analysis. The results to date encourage the belief that it will be possible to compare at least some progestogens by this means, and to establish potency ratios with fiducial limits of error. For this purpose, however, more rigidly-planned trials will be necessary and are at present in progress. For the moment, it can be said that a meaningful dose- (Table I) . With dimethisterone (Secrosteron) no positive responses have been obtained with doses up to 80 mg. Similar negative results have been obtained with 17oc-methallyl-19nortestosterone with doses up to 40 mg. A few tests with 21-methyl norethisterone have shown that the 50% effective dose is certainly greater than 15 mg and probably greater than 30 mg. With 6-methyl-1 7-acetoxy progesterone (Provera), Greenblatt (unpublished data, 1959) has found negative responses with doses up to 30 mg but we have found that the addition of EE3ME, 01 mg daily, gives a 50 % effective dose of approximately 15 mg. A few observations on norethynodrel suggest that the 50 % effective dose for this will be about 15 mg-as compared with 5 mg for Enavid. The addition of cestrogen supplements to dimethisterone has been ineffectual, no positive responses having been obtained with doses of the latter up to 40 mg daily. The reason for the apparent increase in effectiveness of some progestogens, but not others, when small amounts of cestrogen are added is obscure. Withdrawal bleeding.-Patients with longstanding secondary amenorrhmea were employed in this trial and wereinstructed to take progestogen tablets for five days. If a withdrawal bleeding began within the next ten days, they were asked to begin a second course, a month after the first, but at half the dose. If there was no bleeding within ten days of completing the first course, a second course was begun at double the dose. This process of doubling or halving was continued until the maximally ineffective and minimally effective doses were established. Data have been accumulated on norethisterone, norethisterone acetate, Enavid, dimethisterone, 21-methyl norethisterone, 1 7a-methallyl-1 9-nortestosterone and Provera. Meaningful dose-response relationships have not been found, indicating that many uncontrolled factors, other than dose of treatment, influence the result and it is concluded that this criterion is not a suitable one for comparison of potency ratios of progestogens (Table II) .
Effects on vaginal smears.-45 series of vaginal smears, in patients with secondary amenorrhcea given progestogens, have been studied. In 23, treatment produced no change. With norethisterone, 6 series showed progestational and 2 showed cestrogenic changes while 5 showed no change. With norethisterone acetate, 4 series showed progestational and 3 cestrogenic changes while 12 showed no change. With Enavid all series showed some changes-6 progestational and 2 cestrogenic. With dimethisterone, none of 6 series showed any change. It is concluded that vaginal smear changes are not likely to provide a suitable criterion for the comparison of progestational activity.
Summary.-Of a number of criteria considered for the determination of the relative potency of progestogens in the human, postponement of menstruation in normal women given the drug for twenty days from the twentieth day of the cycle seems most likely to provide data on which statistical evaluation of potency ratios may be made. The 50 % effective doses for some progestogens are as follows: norethisterone (Primolut N) 4-25 mg, norethisterone acetate 10-25 mg, norethynodrel + ethynylcestradiol-3methyl ether (Enavid) 5 mg, dimethisterone (Secrosteron) more than 80 mg. Observations on withdrawal bleeding and vaginal smear changes in women with secondary amenorrhoea make it unlikely that these will provide suitable criteria for the comparison of progestational activity.
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